Fidelity Health Services and Nuron Partner to Automate Pharmacovigilance with AI

Fidelity Health Services, a leading pharmacovigilance service provider, and Nuron inc., a pioneering AI-ML platform, today announced a collaboration to automate various pharmacovigilance activities performed by Fidelity Health Services using Nuron's industry-leading AI platform. This partnership has the potential to revolutionize the global pharmacovigilance market, streamlining a critical process for pharmaceutical companies.

Pharmacovigilance, the process of detecting, assessing and monitoring the safety of medicinal products, is becoming increasingly crucial for pharmaceutical companies as they develop and market new drugs and equally crucial for the already approved drugs. Traditional methods of performing various activities in pharmacovigilance have found to be time-consuming and labour-intensive, often relying on manual data analysis and review. This can lead to delays in identifying potential safety concerns affecting the patient safety.

Nuron's AI platform leverages the power of artificial intelligence & machine learning along with automation and prediction to address these limitations. By analyzing the massive amounts of data from various sources, including global literature, clinical trial data, electronic health records, and social media, the platform can help Fidelity Health Services’ technical experts to process and assess the safety data with a lightning speed using AI which eventually results in identifying the trends and potential safety signals much faster and more efficiently and accurately than traditional methods.

"We are excited to partner with Nuron to leverage their innovative AI technology," said Dr. Pramod Dhembare, managing director of Fidelity Health Services. "In today’s era no one is unaware about the power of AI and to utilize it for our business domain i.e. pharmacovigilance and drug safety, we are thrilled to collaborate with the industry best AI platform providers. This collaboration will allow us to improve the efficiency and accuracy of our pharmacovigilance efforts by reducing manual efforts in process leveraging benefits to our clients. By automating repetitive tasks and enabling real-time data analysis, AI can significantly enhance our ability to identify and address potential drug safety issues, ultimately ensuring the safety of patients."

Dr. Nitin Kumar, CEO of Nuron, echoed Dr. Dhembare's sentiment. "Our partnership with Fidelity Health Services is a significant step forward in the development of AI-powered pharmacovigilance," he said. "We believe that our technology has the potential to transform the pharmacovigilance market and make medications safer for everyone. AI and automation hold immense potential to revolutionize pharmacovigilance by enabling faster detection of safety concerns, improved data analysis, and ultimately, safer medications for patients worldwide."

This collaboration between Fidelity Health Services and Nuron is a testament to the growing importance of pharmacovigilance and the transformative potential of AI in this critical field. As the pharmaceutical industry continues to develop more complex and targeted drugs, robust safety monitoring systems become even more essential. AI technology offers a powerful solution, paving the way for a future where medications are not only effective but also demonstrably safe for patients.

For more information on Nuron and our AI-driven solutions, visit www.nuron.io

Contact: